Collaborate Corporation delivers strong March quarter performance

|

Published 29-MAR-2017 12:59 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Collaborate Corporation (ASX:CL8) could eclipse its 12 month record closing high of 2.6 cents after providing an extremely positive update regarding the company’s DriveMyCar business.

While management had already flagged a strong March quarter earlier in the month due to a robust performance in a normally unseasonal period, the figures released today reflect impressive trading on all metrics.

These have had a significant impact on the top line with gross revenue in the March quarter up 13% on the December quarter, the latter traditionally being the strongest three month period in the year.

Importantly, a 90% increase has been achieved in Net Rental Days Booked which captures all days in a booking including those days that are realised in the current month and those days that will be realised in future months.

As booking growth accelerated throughout March, and with many of the bookings for periods of more than 30 days, a significant proportion of revenue from these Net Rental Days Booked will be realised in the June 2017 quarter.

Based on confirmed bookings as at March 28, the forward revenues that will be realised in April 2017 already exceed the revenues achieved in April 2016.

However this company is in its early stages and interested investors should seek professional financial advice.

Importantly, management has reduced costs while growing revenues at a rapid rate, reflecting well on its credibility given the usual financial impost in growing businesses from the ground up.

The negotiation of a 35% reduction in the cost of DriveMyCar’s insurance policy should translate to a 10% improvement in gross profit commencing in the June 2017 quarter.

This has been central to the group’s overall cost-out achievements, and looking at the broader picture Chief Executive Chris Noone said, “With a higher revenue trajectory and lower costs, we look forward to reporting very strong results in the next quarter and beyond as the DriveMyCar business accelerates”.

Looking at some of the key takeaways from the March quarter performance, there was a 77% increase in Net Rental Days Booked in March compared with February 2017. Total Net Rental Days Booked in the March 2017 quarter exceeded 20,000 days.

CL8’s achievement of full utilisation from the fleet inclusion of 101 Subaru Imprezas, a development that only occurred in mid-February, is a reflection of DriveMyCar’s ability to quickly take advantage of new opportunities, indicating a thorough knowledge of end markets and its strong relationships with industry participants.

Rental days booked for UberX rentals increased 265% on a quarter on quarter basis. Rideshare rentals contributed 27% of gross revenue in the March 2017 quarter, up from 18% in the December 2016 quarter. This area of the business is shaping up as one that can deliver exponential growth off a relatively fixed cost base in the near to medium-term.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X